BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23072430)

  • 1. Human papillomavirus DNA and E6/E7 mRNA testing as triage in liquid-based cytology samples from primary screening.
    Andersson S; Mints M; Weiderpass E; Johansson B
    Curr Pharm Des; 2013; 19(8):1508-15. PubMed ID: 23072430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
    Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
    J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus (HPV) E6/E7 mRNA detection in cervical exfoliated cells: a potential triage for HPV-positive women.
    Yao YL; Tian QF; Cheng B; Cheng YF; Ye J; Lu WG
    J Zhejiang Univ Sci B; 2017 Mar.; 18(3):256-262. PubMed ID: 28271661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
    Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
    J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical application of HPV E6/E7 mRNA testing in triaging women with atypical squamous cells of undetermined significance or low-grade squamous intra-epithelial lesion Pap smear: A meta-analysis.
    Yang L; Zhu Y; Bai Y; Zhang X; Ren C
    J Cancer Res Ther; 2017; 13(4):613-620. PubMed ID: 28901302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
    Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
    Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E6/E7 mRNA expression analysis: a test for the objective assessment of cervical adenocarcinoma in clinical prognostic procedure.
    Hovland S; Muller S; Skomedal H; Mints M; Bergström J; Wallin KL; Karlsen F; Johansson B; Andersson S
    Int J Oncol; 2010 Jun; 36(6):1533-9. PubMed ID: 20428778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis.
    Wang-Johanning F; Lu DW; Wang Y; Johnson MR; Johanning GL
    Cancer; 2002 Apr; 94(8):2199-210. PubMed ID: 12001118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications.
    Varnai AD; Bollmann M; Bankfalvi A; Speich N; Schmitt C; Griefingholt H; Kovács K; Klozoris C; Bollmann R
    Oncol Rep; 2008 Feb; 19(2):457-65. PubMed ID: 18202795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2011 Feb; 49(2):557-64. PubMed ID: 21147950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology.
    Rijkaart DC; Heideman DA; Coupe VM; Brink AA; Verheijen RH; Skomedal H; Karlsen F; Morland E; Snijders PJ; Meijer CJ
    J Clin Microbiol; 2012 Jul; 50(7):2390-6. PubMed ID: 22553244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology.
    Alaghehbandan R; Fontaine D; Bentley J; Escott N; Ghatage P; Lear A; Coutlee F; Ratnam S
    Diagn Cytopathol; 2013 Sep; 41(9):767-75. PubMed ID: 23341349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human papillomavirus genotype distribution and E6/E7 oncogene expression in Turkish women with cervical cytological findings.
    Tezcan S; Ozgur D; Ulger M; Aslan G; Gurses I; Serin MS; Giray BG; Dilek S; Emekdas G
    Asian Pac J Cancer Prev; 2014; 15(9):3997-4003. PubMed ID: 24935586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic validity of human papillomavirus E6/E7 mRNA test in cervical cytological samples.
    Liu TY; Xie R; Luo L; Reilly KH; He C; Lin YZ; Chen G; Zheng XW; Zhang LL; Wang HB
    J Virol Methods; 2014 Feb; 196():120-5. PubMed ID: 24216236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
    Rezhake R; Hu SY; Zhao S; Xu XQ; Zhao XL; Zhang L; Wang Y; Zhang X; Pan QJ; Qiao YL; Zhao FH
    Int J Cancer; 2019 Jan; 144(1):34-42. PubMed ID: 29943809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women.
    Duvlis S; Popovska-Jankovic K; Arsova ZS; Memeti S; Popeska Z; Plaseska-Karanfilska D
    J Med Virol; 2015 Sep; 87(9):1578-86. PubMed ID: 25880030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia.
    Tropé A; Sjøborg K; Eskild A; Cuschieri K; Eriksen T; Thoresen S; Steinbakk M; Laurak V; Jonassen CM; Westerhagen U; Jacobsen MB; Lie AK
    J Clin Microbiol; 2009 Aug; 47(8):2458-64. PubMed ID: 19535524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion.
    Molden T; Kraus I; Karlsen F; Skomedal H; Nygård JF; Hagmar B
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):367-72. PubMed ID: 15734959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus oncogene mRNA testing for the detection of anal dysplasia in HIV-positive men who have sex with men.
    Silling S; Kreuter A; Hellmich M; Swoboda J; Pfister H; Wieland U
    J Clin Virol; 2012 Apr; 53(4):325-31. PubMed ID: 22261122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.